SCHEMBL28612192

SCHEMBL28612192

C=CCCC(=O)CCCNC(=O)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.67
TGM2 P21980 1/20 0.63
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KEAP1 Q14145 2/20 0.52
NFE2L2 Q16236 2/20 0.52
FOLH1 Q04609 3/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204298 0.88 TGM2 (0.71) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL485753 0.85 TGM2 (0.66) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL16409727 0.83 HTT (0.72) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL28295609 0.82 HTT (0.81) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL23679979 0.82 HTT (0.67) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL10947796 0.81 HTT (0.78) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL319161 0.81 HTT (1.00) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL504964 0.81 TGM2 (0.64) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL22163638 0.81 TGM2 (0.61) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL18254066 0.80 HTT (0.81) HTTTGM2LMNASMN1; SMN2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113087700-B Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2023-03-14 CN disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 EP disclosed
CN-113087700-A Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2021-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS HTT 948/4885TGM2 1441/4885LMNA 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.